PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 30.51M | 37.08M | 20.54M | 15.61M | 13.44M |
| Total Receivables | 429.20K | 240.80K | -- | 5.00M | 4.61M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 32.00K | 96.90K | 158.70K | 503.10K | 238.20K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | 1.91M | 820.00K |
| Total Current Assets | 30.97M | 37.42M | 20.70M | 23.02M | 19.11M |
|
|
|||||
| Total Current Assets | 30.97M | 37.42M | 20.70M | 23.02M | 19.11M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | 1.55M | 1.55M | 1.55M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 5.74M | 9.33M | 11.16M | 10.66M | 4.82M |
| Total Assets | 36.71M | 46.75M | 55.87M | 55.98M | 45.11M |
|
|
|||||
| Total Accounts Payable | 390.50K | 271.10K | 1.20M | 1.02M | 465.20K |
| Total Accrued Expenses | 345.70K | 497.80K | 345.70K | 345.70K | 345.70K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 32.50K | 57.50K | 132.50K | 210.40K | 250.00K |
| Total Other Current Liabilities | 32.50K | 57.50K | 132.50K | 210.40K | 250.00K |
| Total Current Liabilities | 768.70K | 826.40K | 1.68M | 1.58M | 1.06M |
|
|
|||||
| Total Current Liabilities | 768.70K | 826.40K | 1.68M | 1.58M | 1.06M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 6.13M | 10.95M | 14.79M | 17.85M | 458.00K |
| Total Liabilities | 6.90M | 11.77M | 16.47M | 19.42M | 1.52M |
|
|
|||||
| Common Stock & APIC | 182.01M | 182.72M | 183.14M | 180.61M | 181.55M |
| Retained Earnings | -109.47M | -104.39M | -100.00M | -100.75M | -93.33M |
| Treasury Stock & Other | -44.61M | -44.61M | -44.61M | -44.22M | -44.63M |
| Total Common Equity | 27.93M | 33.71M | 38.53M | 35.65M | 43.59M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 1.89M | 1.27M | 872.30K | 902.00K | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 1.89M | 1.27M | 872.30K | 902.00K | -- |
|
|
|||||
| Total Common Equity | 27.93M | 33.71M | 38.53M | 35.65M | 43.59M |
| Total Preferred Equity | 1.89M | 1.27M | 872.30K | 902.00K | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 29.82M | 34.98M | 39.40M | 36.55M | 43.59M |
|
|
|||||